Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | LPL | P06858 | 2/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134473 | 0.79 | ALDH1A1 (0.55) | ENPP2CA2LPLLIPGTRPV1 | |
| SCHEMBL6257637 | 0.78 | NAMPT (0.33) | ENPP2P4HBALDH1A1 | |
| SCHEMBL1081442 | 0.77 | CA2 (0.43) | ENPP2CA2LPLLIPGTRPV1 | |
| SCHEMBL2728050 | 0.77 | HSD11B1 (0.47) | ALDH1A1HPGDKDM4ETSHR | |
| SCHEMBL9463847 | 0.76 | HSD11B1 (0.37) | CA2ALDH1A1HPGDSMN1; SMN2CA1 | |
| SCHEMBL22858927 | 0.76 | ALDH1A1 (0.50) | ENPP2ALDH1A1HPGDSMN1; SMN2KDM4E | |
| SCHEMBL6969493 | 0.76 | ALDH1A1 (0.35) | ALDH1A1HPGDSMN1; SMN2KDM4ENSD2 | |
| SCHEMBL2701722 | 0.74 | ERN1 (0.53) | CA2TRPV1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9463888 | 0.74 | NSD2 (0.36) | CA2ALDH1A1HPGDSMN1; SMN2CA1 | |
| SCHEMBL21786770 | 0.73 | HDAC4 (0.43) | ENPP2CA2LPLLIPGTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570614-B2 | Phenyl amino pyrimidine compounds and uses thereof | GLAXOSMITH KLINE LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | SIERRA ONCOLOGY, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20210309615-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2021-10-07 | — | — | US | disclosed |
| EP-3023422-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | YM BioSciences Australia Pty Ltd (AU) | 2016-05-25 | — | — | EP | disclosed |
| US-9238628-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM Biosicences Australia PTY LTD (US) | 2016-01-19 | — | — | US | disclosed |
| US-9233934-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2152701-B1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2015-11-11 | — | — | EP | disclosed |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2014-01-02 | — | — | US | disclosed |
| US-8486941-B2 | Phenyl amino pyrimidine compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-07-16 | — | — | US | disclosed |
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE LLC | 2010-08-05 | — | — | US | disclosed |
| EP-2152701-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | Cytopia Research Pty Ltd (AU) | 2010-02-17 | — | — | EP | disclosed |
| WO-2009029998-A1 | RETROMETABOLIC COMPOUNDS | CYTOPIA RESEARCH PTY LTD (AU) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008109943-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD (AU) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197671-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | ENPP2 1164/4885CA2 4781/4885LPL 4174/4885 |
| US-12570614-B2 | Phenyl amino pyrimidine compounds and uses thereof | JAK1, JAK2, JAK3 | ENPP2 3061/4885CA2 3994/4885LPL 4769/4885 |
| US-20140011803-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | ENPP2 1164/4885CA2 4781/4885LPL 4174/4885 |
| US-20210309615-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | ENPP2 1164/4885CA2 4781/4885LPL 4174/4885 |
| US-20220388967-A1 | Phenyl Amino Pyrimidine Compounds and Uses Thereof | JAK2, JAK1, JAK3 | ENPP2 1164/4885CA2 4781/4885LPL 4174/4885 |
| US-20140005180-A1 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | ENPP2 1164/4885CA2 4781/4885LPL 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.